LEXINGTON, Mass., June 1, 2021 /PRNewswire/ -- Curis, Inc.
(NASDAQ: CRIS), a biotechnology company focused on the development
of innovative therapeutics for the treatment of cancer, today
announced the virtual symposium, "VISTA: A New Immune Checkpoint in
Cancer, Autoimmunity and Beyond," taking place on June 18, 2021, 9:00-1:15
PM ET.
Leaders in immunology across industry and academia will gather
to discuss emerging checkpoint molecule, VISTA, including its
function, the role it plays in several disease areas and current
development programs. The event is organized by Curis and will be
hosted by Randolph Noelle, Ph.D.,
Professor of Microbiology and Immunology, Department of
Microbiology and Immunology, Norris Cotton Cancer Center, Geisel
School of Medicine at Dartmouth; and
Padmanee Sharma, M.D., Ph.D., Professor, Department of
Genitourinary Medical Oncology, Division of Cancer Medicine,
University of Texas, MD Anderson Cancer
Center.
"Over the last several years, there have been significant
advancements from both academia and industry in the understanding
and pursuit of VISTA as a target for immunotherapy, including the
advancement of our own anti-VISTA antibody, CI-8993, into clinical
trials," said James Dentzer,
President and Chief Executive Officer of Curis. "This symposium
will bring together leading minds on the forefront of VISTA
research and development to discuss the latest insights into this
emerging checkpoint target and its potential applications in
immuno-oncology, autoimmune diseases and other therapeutic
areas."
Free to attend, the event features agenda topics including:
- Overview of checkpoint therapy
- Introduction of VISTA
- VISTA regulation of the tumor microenvironment in human
cancer
- Discovery of anti-VISTA antibodies
- VISTA counterreceptors
- Industry Panel: VISTA advances into clinical development
To learn more about the symposium and register to attend please
visit, https://bit.ly/3hBzIUj.
About Curis, Inc.
Curis is a biotechnology
company focused on the development of innovative therapeutics for
the treatment of cancer. In 2015, Curis entered into a
collaboration with Aurigene in the areas of immuno-oncology and
precision oncology. As part of this collaboration, Curis has
exclusive licenses to oral small molecule antagonists of immune
checkpoints including the VISTA/PDL1 antagonist CA-170, and
the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase
inhibitor, CA-4948. CA-4948 is currently undergoing testing in a
Phase 1/2 in patients with non-Hodgkin's lymphoma both as a
monotherapy and in combination the with BTK inhibitor ibrutinib.
Curis is also evaluating CA-4948 in a Phase 1/2 trial in patients
with acute myeloid leukemia and myelodysplastic syndromes, for
which it has received Orphan Drug Designation from the U.S. Food
and Drug Administration. In addition, Curis is engaged in a
collaboration with ImmuNext for development of CI-8993, a
monoclonal anti-VISTA antibody, which is currently undergoing
testing in a Phase 1 trial in patients with solid tumors.
Curis is also party to a collaboration with Genentech, a member of
the Roche Group, under which Genentech and Roche are
commercializing Erivedge® for the treatment of
advanced basal cell carcinoma. For more information, visit Curis'
website at www.curis.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/curis-inc-announces-2021-virtual-symposium-vista-a-new-immune-checkpoint-in-cancer-autoimmunity-and-beyond-301302649.html
SOURCE Curis, Inc.